Express Scripts’ Payer Clients On Board With Indication-Based Pricing, Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
PBM provides an update on its indication-based pricing project for oncology drugs, claiming it has found a way around the Medicaid “best price” dilemma.
You may also be interested in...
Medicare Part D Coverage For Obesity Drugs Urged By House Appropriations Panel
In the report accompanying FY 2023 HHS appropriations legislation, the House committee also addresses biosimilar uptake in Part D, Medicare dispensing fees for oral COVID-19 drugs and NIH grants for expanded access to investigational ALS drugs.
Senate Insulin Bill Focuses On List Prices With Carrot For Manufacturers, Stick For PBMs
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.
Back To The Well: Rebate Reform Rule Delay Would Fund Senate Gun Control Bill Provisions
For biopharma manufacturers, chipping away at the rebate rule is a relatively painless drug pricing “pay for” compared to price control policies.